Figure 2
Restricted infection of CA2 pyramidal cells via injection into the LV. (a) A schematic view of LV injection. (b) GFP expression after LV injection of the AAV2/PHP.eB-SynTetOff-GFP vector. Scale bar, 500 μm. (c) Enlarged view of the CA2 region in (b). Scale bar, 50 μm. (d) Density of GFP-expressing cells in the hippocampal subregions. The lines and rectangle indicate the means and distributions of 25% and 75%, respectively (n = 5 sections from 5 mice, H = 13.7, df = 3, P = 3.4 × 10−3, Kruskal–Wallis test). (e) (Top) Virus dose-dependent increase in the infected cell density in the CA2. The rectangles indicate the means and distributions of 25% and 75% (n = 4–6 sections from 4 to 6 mice). (Bottom) Specificity for infection of CA2 pyramidal cells. Gray area indicates 95% confidence interval (n = 4–6 sections from 4 to 6 mice, F = 4.36, df = 2, P = 0.038, one-way analysis of variance (ANOVA)). (f) LV injection of AAV2/1-SynTetOff-mRFP1 and AAV2/PHP.eB-SynTetOff-EGFP. Scale bar, 200 μm. (g) Enlarged view of the CA2 area in (f). Scale bar, 50 μm. (h) Cell density of RFP- or GFPexpressing cells in the CA2 area. The rectangles indicate the means and distributions of 25% and 75% (n = 4 sections from 4 mice, t = 2.78, df = 6, P = 0.032, two-tailed unpaired Student’s t-test). (i) LV (top) or retro-orbital (bottom) injection of AAV2/PHP.eB-SynTetOff-EGFP in BALB/c mice. Scale bar, 200 μm.
